MX2018004091A - Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis. - Google Patents
Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis.Info
- Publication number
- MX2018004091A MX2018004091A MX2018004091A MX2018004091A MX2018004091A MX 2018004091 A MX2018004091 A MX 2018004091A MX 2018004091 A MX2018004091 A MX 2018004091A MX 2018004091 A MX2018004091 A MX 2018004091A MX 2018004091 A MX2018004091 A MX 2018004091A
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- treatment
- antagonists
- atopic dermatitis
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides antagonists of IL-17C for use in the treatment and/or prevention of atopic dermatitis and related conditions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15188355 | 2015-10-05 | ||
PCT/EP2016/073776 WO2017060289A1 (en) | 2015-10-05 | 2016-10-05 | Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018004091A true MX2018004091A (en) | 2018-07-06 |
Family
ID=54256681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018004091A MX2018004091A (en) | 2015-10-05 | 2016-10-05 | Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis. |
Country Status (13)
Country | Link |
---|---|
US (1) | US10604566B2 (en) |
EP (1) | EP3359161A1 (en) |
JP (1) | JP2018529704A (en) |
KR (1) | KR20180058806A (en) |
CN (1) | CN108135913A (en) |
AU (1) | AU2016335017A1 (en) |
CA (1) | CA3000779A1 (en) |
HK (1) | HK1257289A1 (en) |
IL (1) | IL258112A (en) |
MX (1) | MX2018004091A (en) |
RU (1) | RU2018114657A (en) |
WO (1) | WO2017060289A1 (en) |
ZA (1) | ZA201802501B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230203149A1 (en) | 2017-09-25 | 2023-06-29 | Morphosys Ag | Treatment of atopic dermatitis |
GB201803563D0 (en) | 2018-03-06 | 2018-04-18 | Galapagos Nv | Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
PT1076703E (en) | 1998-05-15 | 2007-10-10 | Genentech Inc | Therapeutic uses of il-17 homologous polypeptides |
US20040197306A1 (en) * | 2000-05-24 | 2004-10-07 | Gorman Daniel M. | Mammalian receptor proteins; related reagents and methods |
AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
CN101068835A (en) * | 2004-10-18 | 2007-11-07 | 津莫吉尼蒂克斯公司 | Soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners and methods of using in inflammation |
BRPI0516603A (en) * | 2004-10-18 | 2008-09-16 | Zymogenetics Inc | isolated soluble receptor, antibody or antibody fragment, and methods for treating an immune-mediated disease in a patient in need of such treatment, for reducing il-17c-mediated inflammation, for treating a mammal afflicted with an inflammatory disease, and to treat a pathological condition in a patient associated with zcytor21 activity |
WO2007047738A1 (en) * | 2005-10-18 | 2007-04-26 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
CA2666842A1 (en) * | 2006-10-18 | 2008-04-24 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
JPWO2009122748A1 (en) * | 2008-04-04 | 2011-07-28 | 国立大学法人九州大学 | Remedies for respiratory or allergic diseases |
FR2938439B1 (en) * | 2008-11-14 | 2013-03-01 | Fabre Pierre Dermo Cosmetique | EXTRACT OF AERIAL PARTS OF OATS HARVESTED BEFORE EPIAISON |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
JP2014530836A (en) | 2011-10-19 | 2014-11-20 | モルフォシス・アー・ゲー | IL17C antagonist for the treatment of inflammatory disorders |
RU2014121043A (en) * | 2011-10-24 | 2015-12-10 | Эббви Инк. | BISPECIFIC IMMUNO-BINDING AGENTS AIMED AGAINST TNF AND IL-17 |
WO2013186236A1 (en) * | 2012-06-12 | 2013-12-19 | Orega Biotech | Antagonists of il-17 isoforms and their uses |
-
2016
- 2016-10-05 RU RU2018114657A patent/RU2018114657A/en not_active Application Discontinuation
- 2016-10-05 WO PCT/EP2016/073776 patent/WO2017060289A1/en active Application Filing
- 2016-10-05 US US15/764,918 patent/US10604566B2/en not_active Expired - Fee Related
- 2016-10-05 JP JP2018515839A patent/JP2018529704A/en active Pending
- 2016-10-05 CA CA3000779A patent/CA3000779A1/en not_active Abandoned
- 2016-10-05 KR KR1020187011771A patent/KR20180058806A/en unknown
- 2016-10-05 MX MX2018004091A patent/MX2018004091A/en unknown
- 2016-10-05 CN CN201680058453.7A patent/CN108135913A/en active Pending
- 2016-10-05 AU AU2016335017A patent/AU2016335017A1/en not_active Abandoned
- 2016-10-05 EP EP16784415.8A patent/EP3359161A1/en not_active Withdrawn
-
2018
- 2018-03-14 IL IL258112A patent/IL258112A/en unknown
- 2018-04-16 ZA ZA2018/02501A patent/ZA201802501B/en unknown
- 2018-12-21 HK HK18116435.9A patent/HK1257289A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
HK1257289A1 (en) | 2019-10-18 |
US10604566B2 (en) | 2020-03-31 |
EP3359161A1 (en) | 2018-08-15 |
ZA201802501B (en) | 2019-12-18 |
JP2018529704A (en) | 2018-10-11 |
RU2018114657A3 (en) | 2020-02-10 |
KR20180058806A (en) | 2018-06-01 |
CA3000779A1 (en) | 2017-04-13 |
RU2018114657A (en) | 2019-11-07 |
US20180273614A1 (en) | 2018-09-27 |
IL258112A (en) | 2018-05-31 |
AU2016335017A1 (en) | 2018-03-29 |
WO2017060289A1 (en) | 2017-04-13 |
CN108135913A (en) | 2018-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
MX2019003623A (en) | Compositions and methods for treating ophthalmic conditions. | |
MX2018006632A (en) | Bicyclic inhibitors of pad4. | |
MY176855A (en) | Anti-jagged1 antibodies and methods of use | |
MX2020005213A (en) | Mk2 inhibitors and uses thereof. | |
NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
MX2018006700A (en) | Aza-benzimidazole inhibitors of pad4. | |
PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
PH12017501864A1 (en) | Compositions and methods for treating autism | |
SG10202013034QA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
MX2017006019A (en) | Apilimod for use in the treatment of melanoma. | |
IL263477A (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
PH12017501022A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
MX2016016233A (en) | Anti-lgr5 antibodies and uses thereof. | |
PH12016501838A1 (en) | Compounds and their methods of use | |
MX2017013729A (en) | Specific detection of clusterin isoforms. | |
IL251880A0 (en) | Compositions for treating acute, post-operative, or chronic pain and methods of using the same | |
PL3122367T3 (en) | Compositions based on saffron for the prevention and/or treatment of degenerative eye disorders. | |
MX2022011897A (en) | Methods and compositions for treatment of cartilage damage and arthritis. | |
PL3197556T3 (en) | Composition for the prevention and/or treatment of allergy symptoms | |
MX2015009153A (en) | Use of alpha 7 nicotinic acetylcholine receptor agonists. | |
HK1257289A1 (en) | Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis | |
GB2581876B (en) | Compositions for use in the treatment of endometrial disorder | |
DK3313207T3 (en) | Compositions and methods for the treatment of malnutrition | |
EP3294339A4 (en) | Methods and compositions for the treatment of arthritis |